S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Wei Gang Tong,Alfonso Quintás-Cardama,Tapan M. Kadia,Gautam Borthakur,Elias Jabbour,Farhad Ravandi,Stefan Faderl,William G. Wierda,Sherry Pierce,Jianqin Shan,Carlos E. Bueso-Ramos,Hagop M. Kantarjian,Guillermo Garcia-Manero +12 more
TL;DR: Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow.
Journal ArticleDOI
Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence
Stefan Faderl,Alessandra Ferrajoli,William G. Wierda,Susan O'Brien,Susan Lerner,Michael J. Keating +5 more
TL;DR: A previous study of intravenous bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4‐week treatment period.
Journal ArticleDOI
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Deborah A. Thomas,Elihu H. Estey,Francis J. Giles,Stefan Faderl,Jorge E. Cortes,Michael J. Keating,Susan O'Brien,Maher Albitar,Hagop M. Kantarjian +8 more
TL;DR: Although there appears to be some evidence of biological activity, single agent thalidomide is not an optimal choice of therapy for salvaging patients with relapsed‐ or refractory‐AML, and analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy.
Journal ArticleDOI
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Regimen for Heavily Treated Patients with CLL.
William G. Wierda,Susan O'Brien,Stefan Faderl,Alessandra Ferrajoli,Farhad Ravandi-Kashani,Jorge E. Cortes,Francis J. Giles,Michael Andreeff,Charles Koller,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +11 more
TL;DR: The rationale for the CFAR regimen for previously treated patients with CLL was that alemtuzumab, the mAb against CD52, is highly effective at clearing disease from bone marrow, the usual site of residual disease following purine analogue-based treatment.
Journal ArticleDOI
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
Aziz Nazha,Jorge E. Cortes,Stefan Faderl,Sherry Pierce,Naval Daver,Tapan M. Kadia,Gautam Borthakur,Raja Luthra,Hagop M. Kantarjian,Farhad Ravandi +9 more
TL;DR: It is concluded that FLT3-ITD mutations are unstable at follow up and may occur for the first time at relapse and is not a reliable marker for minimal residual disease in acute myeloid leukemia.